Podcasts about Personalized medicine

What if your healthcare team already knew what happened during your hospital stay — before you even explained it? What if someone on your care team noticed you were struggling on a Saturday and simply showed up? In this episode, Jamie sits down with Christopher Laffey, Nurse Practitioner at Your Health, to break down what a truly connected, proactive model of care actually looks like when it's working. Christopher practices in North Charleston, SC, where his team — nurses, therapists, social workers, community health workers, and more — functions less like a traditional office practice and more like a living, breathing safety net woven around each patient's real life. What you'll hear in this episode: Why most patients are failing not because nobody cares, but because the system itself is fragmented — and what doing it differently actually looks like on a Tuesday morning The real difference between "patient-centered" as a marketing phrase and patient-centered as a daily practice (hint: it involves seeing the medication bottles on the kitchen table) A powerful real-life story of a bedbound patient whose caregiver suddenly disappeared — and how the team mobilized over a weekend, on their own time, to prevent a hospitalization The single mindset shift every clinician needs to make the transition from visit-based thinking to longitudinal care Why "value-based care" doesn't mean discounted care — it means the organization is accountable for your outcomes, not just your appointments If you've ever left a doctor's appointment feeling more confused than when you walked in, this episode will show you what healthcare can feel like when it's actually designed around you. www.YourHealth.Org

In this special replay, BS Free MD host Dr. May Hindmarsh steps out from behind the microphone and into the guest chair. Originally recorded for the Hotflash Inc. podcast with host Anne-Marie McQueen, this candid conversation explores Dr. May's personal journey through menopause, hormone therapy, histamine intolerance, epigenetics, and the unexpected challenges she faced when conventional solutions didn't provide the answers she was seeking. After more than 30 years practicing medicine, Dr. May found herself navigating a complex health journey that included severe hot flashes, migraines, sleep disruption, anxiety, panic attacks, elevated heart rate, and symptoms that persisted despite hormone replacement therapy. As both physician and patient, she began asking deeper questions about genetics, hormone metabolism, mast cell activation, and individualized care. Together, Anne-Marie and Dr. May discuss the importance of critical thinking in medicine, the dangers of one-size-fits-all approaches, and why listening to your own body may be one of the most important skills in healthcare. In This Episode Why Dr. May and Dr. Tim launched BS Free MD Lessons learned from practicing medicine through the COVID era What happened when hormone therapy stopped working as expected Histamine intolerance and mast cell activation explained The role of MTHFR, COMT, and epigenetics in hormone metabolism Why some women thrive on hormone therapy while others struggle Trauma, stress, and their impact on health outcomes The growing movement toward personalized medicine How to navigate conflicting health information Learning to trust your body's signals About Dr. May Hindmarsh Dr. May Hindmarsh is a retired family physician with more than three decades of experience practicing medicine in Canada and the United States. Alongside her husband, Dr. Tim Hindmarsh, she co-hosts BS Free MD, where they challenge conventional narratives, explore emerging health topics, and encourage listeners to think critically about medicine, wellness, and personal responsibility. Original Interview This episode originally aired on the Hotflash Inc. podcast and is being republished on BS Free MD with permission. Connect with BS Free MD Website: https://www.bsfreemd.com Podcast: https://www.bsfreemd.com/podcast YouTube: https://www.youtube.com/@BSFreeMD Disclaimer The information shared in this episode is for educational and informational purposes only and should not be considered medical advice. Always consult your healthcare professional regarding your individual health needs.

What is precision medicine, and how should precision medicine be handled in the face of guidelines and protocols? In this episode of the Society of Critical Care Medicine (SCCM) Podcast, Diane C. McLaughlin, DNP, AGACNP-BC, CCRN, FCCM, speaks with Michael R. Pinsky, MD, FAPS, MCCM, about his Thought Leader presentation at the 2026 Critical Care Congress, The Effective Management of Shock: Moving From Physiology to Guidelines to Precision Medicine and Ultimately Personalized Medicine. The panel also discusses how to titrate care for individual patients. Protocols and guidelines are the foundation for patient care and are instrumental for having all healthcare professionals on the same baseline when treating patients. Precision medicine involves individualizing care for a specific patient, and Dr. Pinsky emphasizes that guidelines should never supersede an understanding of pathophysiology at the bedside, including observing your patient and paying attention to how individual patients respond to specific treatments. Monitoring the individualized response is required for the best care. Michael R. Pinsky, MD, FAPS, MCCM, is a professor of critical care medicine, bioengineering, and anesthesiology at the University of Pittsburgh in Pittsburgh, Pennsylvania, USA. He is also Docteur Honoris Casusa at the Université René Descartes Paris V School of Medicine in Paris, France. In 2012, he became one of the first 20 critical care physicians to receive a Master of Critical Care Medicine (MCCM) from SCCM. He is currently an emeritus (honorary) at UPMC. At the University of Pittsburgh, he is vice-chair emeritus for the Department of Critical Care Medicine and a faculty member at the Center for Critical Care Nephrology and the Center for Military Medicine Research. Resources referenced in this podcast: The Effective Management of Shock: Moving From Physiology to Guidelines to Personalized Medicine

This episode explores the rapidly evolving field of functional genetics and how it’s changing the future of healthcare. Dr. Sam Shay shares how understanding genetic predispositions can help individuals make smarter decisions around diet, exercise, recovery, inflammation management, and stress resilience. Rather than viewing genes as fixed destiny, Dr. Shay explains how epigenetics allows us to influence gene expression through lifestyle choices. He breaks down complex genetic concepts into simple, actionable insights and explains why personalized medicine is the next frontier in health optimization. Listeners will gain practical strategies for understanding their own biology and learn how inflammation, nutrition, detoxification, vitamin D receptors, methylation, and exercise genetics all contribute to long-term wellbeing. ◉

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the dynamic landscape of the pharmaceutical and biotech sectors, a domain experiencing profound changes marked by leadership transitions, regulatory challenges, and groundbreaking scientific advancements. Recent developments within the FDA highlight significant shifts as the agency finds itself at a critical juncture following the departure of Commissioner Marty Makary. This leadership vacuum presents an unprecedented challenge for the FDA, with analysts predicting a prolonged period of uncertainty. Such transitions hold considerable implications for the regulatory framework, potentially influencing drug approval processes and the strategic direction of the agency at large. Amidst this backdrop, industry insiders have proposed Richard Pazdur, a former cancer regulator renowned for his impactful tenure, as a potential successor. His appointment could introduce stability and renewed focus on regulatory frameworks that encourage innovation while upholding stringent safety standards. The recent spate of exits at the FDA, including Vinay Prasad's departure, underscores an urgent need for steady leadership capable of navigating the intricacies of modern drug regulation effectively. In response to these leadership changes, the stock market has shown some volatility, with shares of companies such as uniQure and Replimune experiencing a surge following Makary's exit. However, analysts caution against premature optimism, emphasizing that substantial regulatory relief is unlikely without broader systemic changes. The industry must advocate for policies that sustainably support innovation in light of these shifts. Turning to scientific developments, Lilly's next-generation obesity drug has emerged as a beacon of hope for metabolic disorder treatments. This triple agonist has demonstrated impressive weight loss results in clinical trials, comparable to those achieved through bariatric surgery. Such breakthroughs underscore the critical importance of investing in novel therapeutics that address significant health challenges with high unmet needs. Meanwhile, Amgen's rare disease drug Tavneos is witnessing regulatory progression in Japan after overcoming initial safety concerns. The decision to allow new patient access following a reversal reflects evolving attitudes toward risk-benefit analysis in rare disease treatments. This trend aligns with broader movements in personalized medicine where targeted therapies are gaining precedence despite complex regulatory landscapes. However, beneath these advancements lie economic pressures starkly illustrated by CEO compensation ratios in relation to median employee wages. These disparities raise pertinent questions about resource allocation and investment priorities within pharmaceutical organizations. Such financial dynamics could significantly influence both the pace and direction of future innovations. In oncology, efforts to tackle challenging indications continue with emerging treatments like Revolution's pancreatic cancer drug making headlines. Companies such as Immuneering and Actuate are at the forefront of striving to surpass existing breakthroughs, underscoring competitive innovation as a defining trait of today's biotech landscape. As we reflect on these transformative times within the pharmaceutical and biotech industries, it becomes evident that they are navigating a complex interplay between regulatory upheavals and scientific milestones. The potential appointment of leaders like Richard Pazdur at the FDA may well shape future regulatory directions. Simultaneously, pioneering drugs such as Lilly's obesity treatment exemplify therapeutic advancements poised to redefine patient care paradigms. Nevertheless, financial pressures coupled with market dynamics continue to present formidable obstacles requiring strategic foresight and collaboration among stakeholders to maintain innovation momentum. As these sectors evolve, striking a delicate balance between rigorous regulation and scientific progress will be paramount for advancing public health goals effectively. Thank you for tuning into Pharma Daily. Stay informed and stay ahead with us as we continue to explore these pivotal developments in the world of pharmaceuticals and biotechnology.Support the show

Building on the concepts introduced in the previous episode Rethinking the Design and Conduct of Kidney Trials, this episode explores how innovative ideas in nephrology research can be translated into practical trial strategies. Experts discuss novel approaches to trial design, evolving endpoint selection, and the importance of engaging patients, clinicians, regulators, and other stakeholders throughout the research process. Drawing on insights from the ISN Consensus Meeting on Changing Paradigms of Studies in CKD (Vancouver, Nov 22-23, 2024), the discussion highlights how more pragmatic and implementation-focused trials can help generate evidence that is meaningful for clinical practice and patient care worldwide. Speakers Adeera Levin Professor of Medicine, University of British Columbia, Canada, and Past-President of the International Society of Nephrology (ISN). Dr. Levin is a global leader in kidney health research, with extensive experience in chronic kidney disease (CKD) management, clinical trials, and international health system strengthening. David Wheeler Professor of Kidney Medicine at University College London, UK and Honorary Consultant Nephrologist at the Royal Free Hospital. His research focuses on the management of chronic kidney disease and the evaluation of therapies through large-scale clinical trials. He was co-principal investigator of the landmark DAPA-CKD trial and served as Co-Chair of KDIGO from 2012–2019.  Kevin Weinfurt Professor and Vice Chair of Faculty, Department of Population Health Sciences, Duke University School of Medicine, USA. Dr. Weinfurt is a behavioural scientist specializing in patient-reported outcomes (PROMs), ethical aspects of research participation, and improving the relevance of clinical trials to patients lived experiences. Hiddo J. Lambers Heerspink Professor of Clinical Trials and Personalized Medicine, University Medical Center Groningen, The Netherlands. Dr. Heerspink's work bridges pharmacology, nephrology, and precision medicine, focusing on optimizing kidney and cardiovascular outcomes through innovative clinical trial design and biomarker discovery. To read more, explore the related paper Changing Paradigms of Studies in Kidney Diseases published in Kidney International. 

Hydrogen water—breakthrough or scam? Osteoporosis fixes; Nattokinase for cardiovascular prevention; Why vitamin D helps a subset of diabetics; When oral vitamin D doesn't work, sublingual D may normalize blood levels; Vitamin D found beneficial for colitis; Why fructose stokes food cravings; Flawed fluoridation study claims no IQ harms to kids.

Find out how to avoid toxins in oils and processed foods, boost resilience with teas and glutathione, and detect disease early. #ToxinFreeLiving #EarlyDetection #HealthyAging #HealthTalks

HIV research is one of the clearest examples of molecular biology in action. In this Mol Bio Minutes episode, Dr. Ryan Jeep walks through how fundamental molecular techniques power everything from detection to drug resistance studies to cure-focused research. Ryan begins with HIV biology and detection, explaining how qRT-PCR enables highly sensitive viral load measurement. These assays not only detection strategies but also support research to monitor treatment efficacy and viral rebound. From there, he moves into drug resistance, describing how sequencing, RT-PCR, and cloning strategies help researchers map resistance-associated mutations. By generating recombinant reporter viruses and measuring infectivity against different drugs, scientists can better understand treatment failure and move toward more personalized therapeutic strategies. Finally, Ryan explores cutting-edge cure research, including CRISPR-Cas9 approaches aimed at either disabling integrated viral genomes or engineering HIV-resistant immune cells. Across all three areas one theme remains constant: PCR, sequencing, and cloning form the technological backbone of HIV research. As these tools continue to evolve, so too does the potential to improve outcomes and one day eliminate the virus entirely. Since recording this episode, Ryan has joined KBI Biopharma as a Scientist l in their Formulation Development Group. Helpful resources and links: Access Stanford University's HIV Drug Resistance Database. Visit International AIDS Society's Towards an HIV Cure site, which includes resources.  Access Thermo Fisher PCR resources and products. Learn about RT-qPCR, which is relevant to HIV research.  Explore the cloning technologies referenced in this episode.  Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the transformative dynamics shaping the industry, from financial innovations to regulatory hurdles, each having profound implications for patients and stakeholders alike. The pharmaceutical and biotech industries are in the midst of a transformative period, grappling with the challenge of making advanced therapies, particularly cell and gene therapies, both financially sustainable and accessible. These treatments, often delivered in a single dose with curative potential, pose significant financial challenges due to their high upfront costs. The existing healthcare framework, especially in the U.S., struggles to accommodate these costs because of its reliance on annual insurance cycles and employer-based coverage. This issue is further exacerbated by the pricing strategies adopted by pharmaceutical companies, which often set high list prices to fulfill shareholder expectations while inadvertently creating barriers to accessibility. A notable proposal to address this challenge comes from Jennifer Hinkel, president of Sigla Sciences. She suggests a novel approach through the securitization of therapeutic risks—a financial innovation that holds potential to revolutionize funding for these therapies. Her model envisions a consortium of banks and hedge funds pooling resources to make immediate payments to pharmaceutical companies based on clinical success milestones. This setup allows risk distribution across payers through subscription fees, making high-cost therapies predictable rather than catastrophic expenses. Drawing parallels with parametric insurance models like weather derivatives, Hinkel's approach requires robust data infrastructure for tracking patient outcomes and standardized contracts for clarity in transactions. The successful implementation of this model necessitates bridging communication gaps between finance and biotech sectors, as both operate under different paradigms. Standardizing contracts akin to those used in mortgage-backed securities could further enhance clarity and comparability. Several key developments are essential for this model to materialize: building comprehensive data systems for accurate patient outcome tracking, creating uniform contracts to ease transaction complexities, fostering cross-sector communication for mutual understanding, adapting regulatory frameworks to support these financial instruments while safeguarding patient safety, and educating industry professionals on these innovations' benefits. The implications of such an approach could be groundbreaking, potentially reshaping how therapeutic risks are managed across stakeholders. Despite significant challenges like data infrastructure and cross-sector collaboration, the potential rewards justify further exploration. As biotech innovations continue with advancements like CRISPR gene editing and personalized medicine becoming more prevalent, sustainable financial models will be critical for ensuring these life-saving therapies reach those in need. Turning now to recent developments within the sector that highlight both scientific breakthroughs and regulatory challenges: AstraZeneca faced a setback with its oral selective estrogen receptor degrader camizestrant. An FDA panel voted against its use in first-line settings for hormone receptor-positive, HER2-negative metastatic breast cancer—a blow to AstraZeneca's strategy targeting $5 billion in peak sales. This decision underscores the regulatory hurdles involved in leveraging new mechanisms of action for cancer treatments, emphasizing the necessity for robust clinical data. In another significant shift, Johnson & Johnson has decided to discontinue its CAR-T cell therapy programs despite earlier projections of promising efficacy and potential peak sales Support the show

In this episode of Disruption/Interruption, host KJ sits down with Ome Ogbru, PharmD, CEO and founder of AINGENS, to tackle a decades-old problem hiding in plain sight: life sciences runs on groundbreaking science, but is buried in broken processes. After 20+ years as a clinician, professor, and pharmaceutical executive, Ome reached a breaking point, and instead of finding a new job, he built a new company. He shares how generative AI, used responsibly and strategically, can finally give researchers their time back, cut through misinformation, and help the right information reach the right people faster. Four Key Takeaways: The scientific content workflow is fundamentally broken [4:15] -- Research teams are so resource-strapped that PhDs spend their time managing IT systems instead of doing science. Procuring a software solution could take one to two years and often didn't even solve the right problem. Generative AI isn't the magic wand, it's how you use it [20:01] -- When Ome first tested ChatGPT on biotech content and got poor results, he had a revelation: the tool wasn't the problem. The problem was not knowing how to use it. Pairing AI with deep domain expertise and proper workflows is where the real power lies. The human expert must remain in the driver's seat [32:30] -- AINGENS' platform (MACG) is built so the professional is in control. The AI handles the time-consuming, mundane tasks like literature search, drafting, and formatting, while the expert applies regulatory knowledge, judgment, and guardrails. Misinformation in life sciences is a public health problem [35:49] -- Misinformation travels faster than accurate data. Ome's vision is for generative AI to help industry proactively get accurate, personalized scientific information to the people who need it, patients, clinicians, and researchers alike, before the noise wins. Quote of the Show (35:41):"Misinformation flies faster than correct information." -- Ome Ogbru Join our Anti-PR newsletter where we’re keeping a watchful and clever eye on PR trends, PR fails, and interesting news in tech so you don't have to. You're welcome. Want PR that actually matters? Get 30 minutes of expert advice in a fast-paced, zero-nonsense session from Karla Jo Helms, a veteran Crisis PR and Anti-PR Strategist who knows how to tell your story in the best possible light and get the exposure you need to disrupt your industry. Click here to book your call: https://info.jotopr.com/free-anti-pr-eval Ways to connect with Ome Ogbru:LinkedIn: https://www.linkedin.com/in/ome-ogbru-pharmd/Company Website: http://www.aingens.com How to get more Disruption/Interruption: Amazon Music - https://music.amazon.com/podcasts/eccda84d-4d5b-4c52-ba54-7fd8af3cbe87/disruption-interruption Apple Podcast - https://podcasts.apple.com/us/podcast/disruption-interruption/id1581985755 Spotify - https://open.spotify.com/show/6yGSwcSp8J354awJkCmJlDSee omnystudio.com/listener for privacy information.

In this episode of The Better Life, Dr. Pinkston is joined by compounding pharmacist and national expert Ray Solano from PD Labs. Together, they pull back the curtain on peptides—a powerful but often misunderstood category of therapeutics that is currently reshaping the landscape of modern medicine. While many know peptides through blockbuster GLP-1 weight loss medications or insulin, there is a vast world of "foundational" peptides that conventional medicine often overlooks. Dr. Pinkston and Ray discuss the "gray market" controversy, the rigorous training required for practitioners, and why these amino acid chains are being called the "fountain of youth" for aging populations. Key topics discussed in this episode include: Defining Peptides: Understanding how these amino acid sequences function as "cellular messengers" and the regulatory hurdles that keep them in the spotlight. The Power Players: Deep dives into specific peptides like BPC-157 for inflammation and repair, TB-500 for healing, and CJC/Ipamorelin for muscle growth and anti-aging. The "Toolbox" Approach: Why peptides aren't a "magic bullet" and why they must be paired with solid nutrition, sleep, and professional medical guidance. Gut Health & Inflammation: Exploring why the gut is the epicenter of health and how peptides like KPV help rebuild and protect it. The Future of Tech in Health: Ray announces the launch of a new AI-driven resource at PD Labs to help patients cut through the marketing "noise" and find science-backed answers. See omnystudio.com/listener for privacy information.

What if your body has been reacting to almost everything - and no one told you why? Millions of people are silently suffering from a condition that affects at least 17% of the population, yet remains wildly underdiagnosed. It can look like allergies, hormonal chaos, chronic fatigue, or mystery illness - and today's guest has dedicated her career to finally connecting the dots. In this deeply illuminating episode, Dr. Lotte sits down with Dr. Tania Dempsey, MD - a world-renowned expert in complex, multisystem disease and founder of the AIM Center for Personalized Medicine. Dr. Dempsey is one of the leading voices in Mast Cell Activation Syndrome (MCAS), Lyme disease, and cutting-edge integrative therapies that are changing lives. Together they explore how mast cells work, what triggers them, and why so many people are getting missed by conventional medicine. They also dive into groundbreaking treatments like peptide therapy, SOT therapy, Therapeutic Plasma Exchange, and Methylene Blue that are quietly transforming what's possible in healing. Whether you've been dismissed, misdiagnosed, or are simply searching for answers - this episode will give you language, clarity, and hope.  

On this episode of Chit Chat Stocks, Brett and Ryan speak with Travis Hoium of Asymmetric Investing about how peptides could impact the future of healthcare and what that means for the opportunity in Hims & Hers stock. We discuss:(00:00) Introduction(01:56) Understanding Peptides(09:02) The Economic Impact of Peptides(11:19) Pharmaceutical Companies and Peptide Development(13:40) The Future of Personalized Medicine(16:59) Regulatory Landscape and Government Influence(22:16) Industries Affected by the Peptide Boom(26:59) The Incentive Structure of Healthcare(30:22) Disruption in the Healthcare Industry(32:19) The Hims and Hers Saga(38:24) Management and Future Opportunities(50:47) Asymmetric InvestingAsymmetric Investing: https://www.youtube.com/@asymmetricinvesting*****************************************************Subscribe to our newsletter, Emerging Moats: emergingmoats.com *********************************************************************Chit Chat Stocks is presented by Interactive Brokers. Get professional pricing, global access, and premier technology with the best brokerage for investors today: https://www.interactivebrokers.com/ Interactive Brokers is a member of SIPC. *********************************************************************Check out Value Spotlight: Stockwriteup.com *********************************************************************Fiscal.ai is building the future of financial data.With custom charts, AI-generated research reports, and endless analytical tools, you can get up to speed on any stock around the globe. All for a reasonable price. Use our LINK and get 15% off any premium plan: ⁠https://fiscal.ai/chitchat *********************************************************************Disclosure: Chit Chat Stocks hosts and guests are not financial advisors, and nothing they say on this show is formal advice or a recommendation.

Send us Fan MailOne in six children has a developmental delay, and it takes an average of five years to get a diagnosis for a genetic disease. But it doesn't have to. The technology to get answers in 48 hours already exists.Katherine Stueland, CEO, GeneDx joins host John Driscoll to discuss why rare genetic diseases are far more common than most people realize, how whole genome sequencing is transforming pediatric care, and what it will take to bring precision medicine to every child who needs it.

Send us Fan MailPaper Discussed in this Episode: How artificial intelligence applied to digital pathology could guide treatment personalization in breast cancer. T. Ruelle, T. Grinda, L. Del Mastro, M. Lacroix-Triki, B. Pistilli & G. Gessain. ESMO Real World Data and Digital Oncology 2026.Episode Summary: In this journal club episode, we step into the reality of computational pathology and explore how artificial intelligence is fundamentally transforming breast cancer diagnostics. We examine a comprehensive review detailing how AI not only assists overburdened healthcare systems but also unlocks invisible genomic data straight from a standard $5 hematoxylin-eosin (H&E) glass slide. What happens when a machine can predict complex DNA mutations just by evaluating the structural architecture of cells?In This Episode, We Cover:• The Diagnostic Bottleneck: Understanding the critical worldwide shortage of pathologists colliding with a projected 3.2 million global breast cancer diagnoses by 2050, and why the system is under unprecedented strain.• The Biomarker Battle: Why the human visual cortex struggles to quantify faint immunohistochemistry stains, and how AI acts as a perfect "digital colorimeter". We discuss its near-perfect concordance in assessing crucial biomarkers like Ki-67, ER, PR, PD-L1, and the newly established HER2-low status.• Seeing the Invisible (Predictive AI): How deep learning transcends visual diagnostics to predict treatment outcomes, such as a patient's response to neoadjuvant chemotherapy. We also discuss AI's ability to infer Homologous Recombination Deficiency (HRD) and BRCA1/2 mutations by identifying macroscopic footprints like laminated fibrosis.• Decoding Genomic Assays: The potential to replace expensive, tissue-consuming genomic tests like Oncotype DX with AI models (such as Orpheus) that predict recurrence risk straight from digitized slides, achieving accuracy that rivals the tests themselves.• Roadblocks to Reality: The major clinical friction preventing global rollout. We discuss the steep infrastructure costs of whole-slide scanners, the danger of AI bias across diverse hospital datasets, and the ethical "black box" problem requiring the evolution of transparent, agent-based AI.Key Takeaway: Computational pathology is moving far beyond basic diagnostic assistance. By successfully reading the structural language of biology, AI proves it can extract costly, invisible molecular data from standard biopsies, fundamentally changing the economics and accessibility of global personalized healthcareSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of dynamic changes and strategic shifts reshaping these industries, driven by scientific advancements and regulatory updates. Let's start with Biogen, which recently resolved an investor lawsuit concerning its Alzheimer's drug, Aduhelm. Approved under controversial circumstances by the FDA, Aduhelm faced scrutiny for its efficacy and costs. This settlement is a critical reminder of the importance of transparent communication with investors, especially when navigating high-stakes therapeutic areas like Alzheimer's. The broader implication for pharmaceutical companies is the need to balance innovation with accountability and transparency—a challenge that resonates across the industry. Meanwhile, Pfizer's decision to vacate office space in South San Francisco exemplifies a significant trend toward remote work, accelerated by the COVID-19 pandemic. This shift suggests that traditional workplace models are being reassessed in favor of flexibility and cost efficiency, a change likely to influence real estate investments and organizational structures across biotech firms. Amgen stands out with its notable financial growth highlighted by CEO Robert Bradway's $24.7 million compensation package in 2025. This success underscores Amgen's strategic prowess in maintaining robust performance amidst competitive pressures. Their approach could serve as a blueprint for other firms aiming to achieve sustained growth through innovation and strategic management. On the clinical trial front, Insmed's decision to halt development of Brinsupri after underwhelming mid-stage results illustrates the inherent risks in drug development. This highlights the need for rigorous trial designs and adaptive strategies within development pipelines to address potential setbacks efficiently. Turning to Gilead Sciences, there's a strategic pivot from mergers and acquisitions towards strengthening its internal research pipeline, now described as stronger than ever. This shift away from external acquisitions reflects an industry trend prioritizing internal R&D capabilities, potentially leading to breakthrough therapies that enhance patient care while ensuring sustained business growth. In regulatory developments, GSK's Exdensur received new approval in China, showcasing the ongoing globalization of pharmaceutical markets. Navigating diverse regulatory environments becomes crucial for maximizing drug accessibility worldwide. Another trend is seen through Invivyd's “Antibodies for Any Body” campaign featuring Olympic skier Lindsey Vonn. Leveraging public figures can significantly raise awareness about innovative treatments, playing a crucial role in educating the public about medical advancements. There's also significant financial movement within the sector as Jeito Capital announced a record $1.2 billion fundraising for an independent biopharma-focused European fund. This capital influx is poised to accelerate research and development activities across Europe, potentially leading to new therapeutic breakthroughs. Vivtex Therapeutics' $2.1 billion deal with Novo Nordisk illustrates the power of strategic collaborations in advancing therapeutic solutions and enhancing drug delivery systems—key components for improving patient outcomes. Sidewinder Therapeutics is making strides with a $137 million funding round to develop antibody-drug conjugates (ADCs), highlighting investor confidence in technologies that integrate precision medicine approaches to offer potent cancer treatments with reduced side effects. Astellas Pharma's collaboration with Dyno Therapeutics marks another milestone in gene therapy advancements. A $15 million agreement aims at utilizing engineered adeno-associated virus (AAV) capsids for muscle disorders, proSupport the show

Dr. Hoffman continues his conversation with Dr. Jeffrey Bland, Founder and President of the Personalized Lifestyle Medicine Institute and President of Big Bold Health.

Dr. Jeffrey Bland, Founder and President of the Personalized Lifestyle Medicine Institute and President of Big Bold Health, is described as the “godfather of functional medicine.” He details the origins of functional medicine as a systems-biology, root-cause approach emphasizing diet, lifestyle, and supplements alongside conventional allopathic care, especially for chronic disease. Bland contrasts medication “number needed to treat” examples (statins and TNF-alpha blockers) with personalized lifestyle interventions, noting adherence challenges. He discusses GLP-1 weight-loss drugs as a major pharmacologic advance but raises concerns about long-term effects, discontinuation rates, side effects, and inadequate nutrition if food intake drops. Bland describes research on bitter compounds and gut “taste” receptors influencing GLP-1 and related hormones, links to Blue Zone diets, and introduces Big Bold Health's Himalayan Tartary Buckwheat and minimally processed, sustainably sourced fish oil products, the Omega-3 index, and targeted formulations with lutein/astaxanthin, plus ongoing clinical trials on immune aging and gene expression.

Dr. Hoffman continues his conversation with Dr. Paul Kolodzik of Metabolic MD.

How Continuous Glucose Monitors Can Optimize Metabolic Health—and Where GLP-1 Drugs Fit: Emergency physician-turned-preventive/metabolic medicine specialist Dr. Paul Kolodzik of Metabolic MD reveals how continuous glucose monitors (CGMs) are a tool not only for diabetics but also for non-diabetics and pre-diabetics to personalize diet, sleep, and exercise by seeing real-time glucose patterns instead of relying on fingersticks or A1c averages. Kolodzik describes CGM use in his clinic (two-week diagnostic wear, then therapeutic guidance), highlights insulin resistance, fasting insulin testing, glucose variability, and the role of low-carb eating, intermittent fasting, and strength training to improve metabolic syndrome, triglycerides, and fatty liver. They discuss CGM sourcing/cost, device mechanics and accuracy, possible future noninvasive wearables, and GLP-1/GIP weight-loss drugs, emphasizing supervised, limited-dose use with protein and lifestyle changes to avoid muscle loss and weight regain. A free PDF of Kolodzik's book is offered HERE.  

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.Today, we delve into recent significant advancements and strategic maneuvers reshaping the landscape in these dynamic industries. AstraZeneca has made a notable stride with its chronic obstructive pulmonary disease (COPD) drug candidate, achieving remarkable efficacy in Phase 3 trials. This success is particularly significant given the historical challenges in this therapeutic area, where competitors like Roche and Sanofi have struggled to deliver consistent results. AstraZeneca's achievement not only highlights its innovative clinical development strategies but also offers renewed hope for COPD patients who have long awaited more effective treatment options.In a parallel move, AstraZeneca is pioneering in vivo CAR-T cell therapies, showcasing their potential despite safety concerns following a patient death during trials in China. The therapy's ability to eradicate cancer in three out of five patients underscores its promise as a revolutionary treatment for cancer, illustrating the need for ongoing safety evaluations as this technology develops.Meanwhile, Novartis continues to strategically expand its allergy treatment portfolio with a significant $2 billion acquisition of Excellergy. This deal centers around an anti-IgE program poised to potentially replace Xolair, Novartis's leading allergy medication. Such strategic moves underscore Novartis's commitment to remaining at the forefront of allergy therapeutics by harnessing biotechnological innovations to develop next-generation treatments. This acquisition complements existing assets like Xolair, an IgE blocker now approved for treating food allergies across different age groups, aiming to bolster Novartis's competitive edge in allergy therapeutics by providing a broader array of solutions.Otsuka Pharmaceutical is also making waves with its $1.2 billion acquisition of Transcend Therapeutics. This acquisition focuses on an MDMA analog for psychiatric conditions, marking Otsuka's deepening interest in mental health therapeutics and the burgeoning field of psychedelic compounds as viable psychiatric treatments. This move reflects a broader industry trend towards exploring unconventional therapeutic avenues to address complex mental health issues.On the regulatory front, Takeda is undergoing significant restructuring efforts aimed at achieving $1.3 billion in annual savings through reorganization. This reflects a broader industry trend towards optimizing operations to enhance efficiency and maintain competitiveness in an ever-evolving market landscape.In another noteworthy development, Rocket Pharmaceuticals has secured accelerated FDA approval for Kresladi, a gene therapy targeting severe leukocyte adhesion deficiency-1. This approval highlights the growing potential of gene therapies to meet unmet medical needs for rare diseases and sets an important precedent for other companies seeking expedited regulatory pathways for their gene therapy pipelines.In Alzheimer's research, both Eisai and Alzheon have made significant contributions, especially regarding high-risk patient subsets. Eisai presented real-world data on Leqembi at the AD/PD annual meeting, demonstrating safety and efficacy in patients with specific genetic profiles like APOE4 homozygotes. Concurrently, Alzheon provided insights into its candidate's performance in similar cohorts. These findings underscore personalized medicine's growing importance in neurodegenerative disease treatment.Oncology remains a critical area with Merck's announcement of its planned acquisition of Terns Pharmaceuticals for $6.7 billion. Driven by Terns' promising leukemia drug developments, this acquisition exemplifies how major players are diversifying their oncology pipelines to maintain market leadership amid approaching patent expiraSupport the show

This week Clint speaks with Dr. Shawn McNeil & Dr. Donard.  In this conversation they explore the latest research and clinical practices in psychiatry, focusing on schizophrenia, genetic testing, early detection, and the impact of AI on mental health.    Dr. Shawn McNeil hosts an Apple podcast, "Addiction Medicine: Beyond the Abstract" Addiction Medicine: Beyond the Abstract - Podcast - Apple Podcasts. A quarterly, interactive addiction journal club was discussed, paired with presentation Dr. McNeil discusses on his podcast. https://podcasts.apple.com/us/podcast/addiction-medicine-beyond-the-abstract/id1806152019   Biography Dr. Shawn McNeil is a physician and researcher at LSU Health Shreveport. He is a Clinical Assistant Professor in the Department of Psychiatry and Behavioral Medicine and serves as Program Director of the Psychiatry Residency Program and Director of Neuroinformatics Research. He is a diplomate of the American Board of Psychiatry & Neurology and is board-certified in General Psychiatry and Child & Adolescent Psychiatry. He completed his Psychiatry residency at LSU Health Shreveport and is a recipient of the Resident Recognition Award from the American Psychiatric Association (APA). He also completed his fellowship in Child & Adolescent Psychiatry at LSU Health, serving as chief resident of the program.   Clinically, Dr. McNeil practices at Louisiana Behavioral Health where he serves as Chief Medical Officer. He also supervises residents at the Ochsner LSU Health Ambulatory Care Center. His primary research is clinical in nature. He is Principal Investigator on a clinical trial (Apathy in Schizophrenia, Intra-Cellular Therapies, Inc.) at the LSU Health Psychiatry Research Clinic which is investigating the use of Lumateperone on motivation in patients with psychotic disorders. He previously worked on the Blüm Autism Study (sponsored by Curemark) and the Tapestry Autism Study (sponsored by Axial Therapeutics). He is also the Director of Clinical Research for the Louisiana Addiction Research Center.   Dr. McNeil serves as President of the Louisiana Psychiatric Medical Association (LPMA). He is on the editorial board of the Journal of Addiction Medicine (JAM) and is host of their podcast "Addiction Medicine: Beyond the Abstract". He is a 2018 recipient of the ASAM's Ruth Fox Memorial Endowment Scholarship. He has also served on the editorial board of the APA's American Journal of Psychiatry Resident's Journal and he has been recognized as a Fellow of the APA.   Dr. McNeil was previously a staff physician at the Overton Brooks VA Medical Center and treated veterans in the Post-Traumatic Stress Disorder Clinic. He continues to proudly serve as a Deputy Coroner of Caddo Parish, Louisiana.     Donard Dwyer, PhD Professor of Psychiatry and Behavioral Medicine   Biography Donard Dwyer received his BS degree in Psychology from Tulane University, a Master's degree in education (MEd) from the University of Rochester and his PhD from the University of Alabama at Birmingham (UAB). In addition, to holding positions as a Research Scientist at the Max-Planck Society laboratories in Würzburg, Germany and Director of Immunology at a Cambridge biotechnology company, Dr. Dwyer has spent 32 years in academic research at UAB and LSU Health Shreveport. He is currently professor of Psychiatry and Pharmacology, Toxicology and Neuroscience at LSU Health Shreveport. In addition, he is Vice-Chair for Research in the Department of Psychiatry.   His research interests range broadly from the evolution of protein ligand-receptor interactions, the electronic properties of amino acids and regulation of glucose transport in neurons to behavioral genetics of motivation and movement in C. elegans and the genetic basis for schizophrenia and neuropsychiatric disorders. He is currently focused on the role of insulin signaling pathways in regulation of motivation in “suicidal” worms and characterization of the genetic architecture of schizophrenia with mathematical approaches. Finally, his laboratory is searching for drugs that produce neuroenhancement in cultured neurons as potential treatments for an array of neuropsychiatric conditions.     Medical Trial: https://www.lsuhs.edu/departments/school-of-medicine/psychiatry-and-behavioral-medicine/research   Chapters 00:00 Introduction to the Podcast and Guests 02:27 Overview of Schizophrenia and Motivation Challenges 04:23 The New Drug Adalumid Teparone and Its Potential 07:50 Understanding Schizophrenia: Causes and Risk Factors 12:04 Genetics of Schizophrenia: Myths and Realities 16:20 Enrolling Patients in Clinical Trials 20:49 Genetic Testing and Personalized Medicine in Psychiatry 25:54 Early Signs of Psychosis in Children 30:50 Supporting Families and Community Resources 40:04 The Role of AI in Future Psychiatry 52:17 AI and the Risks of Artificial Relationships 56:35 Conclusion: Hope and the Future of Mental Health Care

​What ​if ​you ​could ​tell ​ahead ​of ​time ​who ​needed ​how ​much ​pain ​relief? ​What ​if ​you ​could ​avoid ​administering ​opioids ​to ​those ​with ​the ​highest ​risk ​of ​addiction, ​even ​if ​they ​didn't ​already ​know ​for ​themselves? What ​if ​you ​could ​help ​ease ​the ​pain ​of ​a ​patient ​in ​need ​and ​be ​sure ​that ​you've ​made ​the ​right ​call? Brian ​Meshkin ​of Proove ​Genomics shares his journey from personal tragedy to pioneering a scoring system that helps clinicians assess pain relief needs based on genetic profiles. Discover how this innovative approach aims to mitigate the opioid crisis by identifying patients at risk of addiction and personalizing pain treatment. Join us for an insightful discussion that blends science, compassion, and the urgent need for change in pain management.Find out more at https://proove.com/

How do the clothes we wear shape not only our comfort, but also our healing, identity, and empowerment as women?In this inspiring conversation, Krista sits down with Keira Kotler, founder of Everviolet, a company dedicated to creating intimate apparel that supports women through the many changing seasons of life. From breast cancer recovery to pregnancy, menopause, and beyond, Keira shares how garments can nurture both body and spirit, offering comfort, inclusivity, and empowerment.This episode explores the intersection of personalized medicine, women's health, and clothing design, reminding us that healing is not only medical but also deeply personal and embodied.Key Topics Covered✨ Keira's Journey – From brand marketing to lingerie design after her own breast cancer diagnosis and bilateral mastectomy. ✨ The Birth of Everviolet – How the lack of supportive, feminine, and comfortable garments inspired her to create a new kind of intimate wear. ✨ Inclusivity in Design – Garments that accommodate reconstruction, prosthetics, asymmetry, surgical drains, and diverse body types. ✨ Fabric Matters – Why natural, breathable, and environmentally conscious fabrics are essential for healing and comfort. ✨ The Beauty of Change – EverViolet's tagline and mission to support women through puberty, pregnancy, postpartum, illness, menopause, and beyond. ✨ Personalized Support – Free fit and style consultations, both in-person and virtual, to help women find their best fit. ✨ Community Storytelling – In Her Words, EverViolet's journal series where women share their health and life journeys.If you wish to learn more from Keira Kotler and her company, Everviolet, check out the following links:Website: Use the code "DNATALKS20" for a 20% off discount at everviolet.com; you may also explore their community series, In Her Words: Journal series on their websiteContact: hello@everviolet.comInstagram: @everviolet ______________________________________________________Keep yourself up to date on The DNA Talks Podcast! Follow our socials below:The DNA Talks Podcast Instagram: @dnatalkspodcastThe DNA Company Instagram: @thednacoThe DNA Company's Official Tiktok Account: @thednaco3Medical Disclaimer:  The information provided in this communication is for general informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read here. If you think you may have a medical emergency, call your doctor or 911 immediately.

In this episode of The Better Life, Dr. Mary Ann Pinkston sits down with Ray Solano of PD Labs to tackle the rising trend of "shortcut healthcare." As more patients turn to automated online platforms for instant prescriptions, our hosts discuss the hidden dangers of self-diagnosis and the critical importance of the patient-physician relationship. From the "Amazon effect" on medical delivery to the upcoming regulatory shifts in the peptide market, this conversation is a must-listen for anyone looking to navigate the complex world of integrative and contemporary medicine safely. Key highlights include: The Telemedicine Trap: Why a 5-minute questionnaire can’t replace a physical exam (and the real-life story of a missed heart failure diagnosis). Health Privilege vs. Health Care: A candid look at celebrity-endorsed weight loss ads and the reality of GLP-1 medications. The Black Market Alert: How government restrictions created a "black market" for counterfeit peptides and what you need to ask your pharmacist. The Peptide Revolution: Exciting news on the return of 14 key peptides (like BPC-157 and Kisspeptin) to state-licensed pharmacies and the debut of new topical, needle-free options. Customized Care: How compounding pharmacies like PD Labs provide affordable, tailored solutions for chronic conditions, longevity, and even prescription-strength skincare for men. See omnystudio.com/listener for privacy information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore the latest news and trends shaping this dynamic industry.Significant strides have been made recently, particularly with the FDA's approval of J&J and Protagonist Therapeutics' novel psoriasis medication, Icotyde. This once-daily oral treatment could disrupt a market dominated by injectable therapies. The convenience of oral administration is likely to improve patient compliance and drive substantial sales, marking a pivotal moment in psoriasis treatment. The Phase 3 ICONIC trial demonstrated substantial efficacy over existing treatments like Bristol Myers Squibb's Sotyktu. This trend towards more patient-friendly options is indicative of a broader industry shift and signifies Protagonist's entry into competitive immunology markets.Turning to biosimilars, Sandoz has expanded its partnership with Samsung Bioepis to commercialize up to five biosimilars, including a version of Takeda's Entyvio. This collaboration highlights the industry's growing reliance on biosimilars as affordable alternatives to branded biologics. Amidst pricing pressures and a global demand for accessible medications, such strategies are becoming increasingly vital.In an ambitious venture, TerraPower Isotopes, backed by the Gates Foundation, is investing $450 million in a plant for producing actinium-225, a rare isotope used in radiopharmaceuticals. This move positions TerraPower as a leader in supplying crucial ingredients for targeted cancer therapies—an area that promises advancements in precision medicine by offering targeted treatments with fewer side effects.Regulatory landscapes are evolving too, with the FDA and NIH committing $150 million towards alternatives to animal testing in drug development. This initiative emphasizes ethical scientific practices and leverages innovative technologies like organ-on-chip systems. Such regulatory support is essential for speeding up drug development while ensuring safety standards remain high.Stem cell therapy also sees promising developments with Aspen Neuroscience's treatment for Parkinson's disease. After one year, all treated patients showed symptom improvement, paving the way for pivotal Phase 3 trials. These results underscore the transformative potential of regenerative medicine in tackling neurodegenerative disorders.As the industry evolves, it faces challenges such as looming patent expirations and intensified competition. These pressures are prompting companies to innovate and reconsider strategies for existing product lines. In response to these challenges, strategic realignments are becoming more common.Meanwhile, Indiana's plan to create 100,000 jobs through a $1 billion strategy highlights regional efforts to establish hubs for life sciences innovation, illustrating the broader economic impact of the biopharma sector.In parallel news, Xaira Therapeutics has raised an impressive $1 billion to leverage AI for drug discovery in inflammatory and immunological research. This underscores growing reliance on AI technologies to accelerate drug development timelines. Crossbow Therapeutics reached a significant milestone by securing $77 million in Series B funding to advance its T-cell engager technology—a promising approach in immuno-oncology that harnesses the immune system against cancer cells.Despite these advancements, economic pressures continue to challenge some companies. Layoffs at Gossamer Bio and Bicycle Therapeutics highlight sector volatility and the need for strategic adaptability. Corporate governance remains under scrutiny as Moderna's CEO compensation package reveals executive priorities amidst revenue shortfalls. Meanwhile, GSK faces criticism over its management practices concerning Flovent, which raises ethical concerns about pricing strategies.In cardiovascular care, Support the show

In this episode of Death Clock, Brent sits down with Dr. Michael Snyder, a Stanford geneticist and leader in precision health research, to explore how wearable technology and continuous biomarker tracking are changing the way we understand disease risk. Dr. Snyder explains how devices like smartwatches can detect early signs of infection, how continuous glucose monitors reveal individual metabolic responses to food, and why dense, longitudinal data may allow us to catch illness long before symptoms appear. They also discuss the limits of consumer health tech, the risk of false positives, and how to think about data without becoming overwhelmed by it. He's a fascinating guest, hope you enjoy.

In this episode of Disruption/Interruption, KJ sits down with Oleg Kovalev, Chief Marketing Officer at Aspect Health, revealing how his company became the #1 women's hormonal health startup in the USA by disrupting traditional PCOS treatment. Discover how continuous glucose monitoring and lifestyle coaching are helping one in five women manage a condition that doctors have been treating wrong for decades—and how this medical innovation is driving explosive business growth. Four Key Takeaways: [4:21] PCOS affects 20% of women and is the #1 cause of infertility - Traditional medicine has underdiagnosed and undertreated PCOS for decades, leaving millions of women without proper answers or solutions beyond pills that mask symptoms. [8:33] Managing glucose levels can dramatically reduce PCOS symptoms - Simple lifestyle changes combined with continuous glucose monitoring help women see real-time correlations between their food choices and symptom improvement, leading to exceptional product retention. [17:24] Data-driven positioning beats gut feeling every time - Aspect Health grew 12x in nine months by systematically testing positioning through paid ads and user behavior metrics rather than relying on intuition or assumptions. [24:11] Ask what you should NOT be doing - Focus and intentionality come from eliminating tasks rather than adding them—the critical question every founder and marketer must answer to achieve breakthrough success. Quote of the Show (8:00):"When women go to doctor and they ask questions about PCOS, in most cases they don't get answers to their questions. Often they are given some standard protocol of taking some kind of pills." - Oleg Kovalev Join our Anti-PR newsletter where we’re keeping a watchful and clever eye on PR trends, PR fails, and interesting news in tech so you don't have to. You're welcome. Want PR that actually matters? Get 30 minutes of expert advice in a fast-paced, zero-nonsense session from Karla Jo Helms, a veteran Crisis PR and Anti-PR Strategist who knows how to tell your story in the best possible light and get the exposure you need to disrupt your industry. Click here to book your call: https://info.jotopr.com/free-anti-pr-eval Ways to connect with Oleg Kovalev LinkedIn: https://www.linkedin.com/in/alecko/Company Website: www.aspect-health.com How to get more Disruption/Interruption: Amazon Music - https://music.amazon.com/podcasts/eccda84d-4d5b-4c52-ba54-7fd8af3cbe87/disruption-interruption Apple Podcast - https://podcasts.apple.com/us/podcast/disruption-interruption/id1581985755 Spotify - https://open.spotify.com/show/6yGSwcSp8J354awJkCmJlDSee omnystudio.com/listener for privacy information.

EPISODE SUMMARY What if we could predict whether a drug will work for a specific person before they ever take it? In this episode, Claudia Garbutt interviews Israeli neuroscientist and biotech entrepreneur Dr. Nisim Perets, founder of Itay&Beyond — a company pioneering patient-derived brain organoids on a chip to accelerate precision medicine for neurological and psychiatric conditions like Autism Spectrum Disorder and epilepsy. Dr. Perets and his team are growing miniature brain tissues from a patient's own cells, placing them on a chip, and measuring their electrical activity to predict how that specific brain might respond to medication. Yes — really. Mini Brains. Massive Breakthroughs.   We talked about... Using lab-grown brain tissue to predict drug responses Neuroscience, nanoparticles & synthetic biology Precision medicine for autism, epilepsy, and psychiatric disorders EPISODE NOTES Dr. Nisim Perets is an Israeli neuroscientist and biotech entrepreneur specializing in drug development, targeted delivery systems, and advanced neurotechnologies. His work focuses on translating cutting-edge neuroscience into real-world therapeutic solutions, including patient-derived lab-grown brain tissues on a chip. Dr. Perets has published multiple high-impact scientific papers and is the inventor of more than ten medical patents. He was part of the scientific founding team of NurExone Biologic (NRX), a company developing nanoparticle-based therapies designed to promote recovery after severe spinal cord injuries. In 2021, he founded Itay&Beyond, a biotechnology company pioneering personalized brain-on-a-chip platforms. The company develops patient-derived lab-grown brain tissues (Organoids) to predict drug efficacy for neurological and psychiatric conditions before clinical use, including Autism Spectrum Disorder and epilepsy, aiming to transform precision medicine in the brain sciences. The company is named after the son of one of the founders, Itay, a young man with low-functioning Autism Spectrum Disorders   Links: https://itayandbeyond.com/ https://www.linkedin.com/in/nisimperets/   --------- Click this link to listen on your favorite podcast player and if you enjoy the show, please leave a rating & review: https://linktr.ee/wiredforsuccess ------------------ Music credit: Vittoro by Blue Dot Sessions (www.sessions.blue) ----------------- Disclaimer: Podcast Episodes might contain sponsored content.

America Out Loud PULSE with Dr. Myriah Hinchey – Childhood vaccines spark intense debate in modern healthcare. Dr. James Neuenschwander explores vaccine history, ingredients, immune vulnerability, and rising chronic illness in children. This conversation examines individualized risk, parental autonomy, informed consent, and the urgent need for transparent safety data and personalized approaches to pediatric health...

In this Your Health University episode, Jamie sits down with Nurse Practitioner, Brooke Howard, President of Clinical Operations, to talk about Biote, wellness, and bioidentical hormone optimization—and why it has been life-changing for both of them. Brooke shares how a trusted colleague pushed her to look deeper when she was exhausted, gaining weight, and “holding it together by a thread.” Jamie opens up about anxiety, ADD medication, and how feeling hormonally balanced gave him the confidence to step into a new chapter. This conversation is for anyone who feels “off,” has been told their labs are “normal,” and wants to explore a more complete picture of wellness. www.YourHealth.Org

America Out Loud PULSE with Dr. Myriah Hinchey – Childhood vaccines spark intense debate in modern healthcare. Dr. James Neuenschwander explores vaccine history, ingredients, immune vulnerability, and rising chronic illness in children. This conversation examines individualized risk, parental autonomy, informed consent, and the urgent need for transparent safety data and personalized approaches to pediatric health...

Reflections on the Peter Attia/Epstein scandal; How to lower lp(a)—does diet help? What are bio-active peptides? Could they stave off kidney disease? Scientists just tested the fittest 81-year-old in the world—here's what they found; Media erroneously report that intermittent fasting is not effective for weight loss; Sugary drinks may stoke anxiety in teens; Omega-3s support kids' reading fluency and spelling scores; Surprising study shows saturated fats not harmful to kidneys.

Dr. Marbas outlines essential lab tests and special panels for vegans, including CBC, B12, vitamin D, omega-3s, iron, and inflammation markers. #VeganHealth #PreventiveLabs #NutritionTracking #WellnessCheck

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant events and decisions in the industry that are shaping the path forward for drug development and patient care.The U.S. Food and Drug Administration (FDA), an agency often at the center of pharmaceutical innovation and scrutiny, has recently made several noteworthy decisions. These decisions not only point to the ongoing regulatory challenges but also highlight scientific advancements within the field.One of the key updates involves the FDA's decision to reject Disc's drug bitopertin, which was intended for the treatment of erythropoietic protoporphyria, a rare blood disease. Despite receiving a national priority voucher for expedited review, the FDA ultimately concluded that the clinical data did not sufficiently support regulatory approval. This decision underscores the FDA's commitment to maintaining rigorous standards even when expedited reviews are in play, emphasizing the necessity of robust clinical evidence for approval.Adding complexity to this situation is the internal dynamics within the FDA itself. Richard Pazdur, a long-standing official at the agency, recently stepped down, revealing disagreements with Commissioner Marty Makary over reducing the number of clinical trials required for new drug applications. Pazdur's departure after an influential 26-year tenure highlights ongoing debates within regulatory bodies on how to balance innovative approval pathways with ensuring safety and efficacy data.In another notable development, Moderna faced setbacks with its mRNA-1010 flu vaccine as the FDA declined to review it. This decision leaves American consumers without access to potentially more effective mRNA-based flu vaccines—a technology embraced by other countries for influenza treatment. This situation points to possible missed opportunities in leveraging cutting-edge vaccine technologies domestically, showcasing both the promise and regulatory complexities surrounding mRNA technology.These regulatory challenges unfold amid leadership changes and strategic shifts within health agencies. For instance, Jim O'Neill's departure from his role as acting director of the Centers for Disease Control and Prevention following Susan Monarez's abrupt ouster illustrates how leadership turbulence can impact policy consistency and strategic direction, potentially affecting how new health initiatives are prioritized and implemented.Meanwhile, companies like Vertex and CRISPR Therapeutics are ambitiously advancing gene therapy solutions such as Casgevy, signaling a broader trend towards personalized medicine and advanced biotechnological approaches. These efforts promise transformative impacts on patient care and reflect an industry-wide move towards precision medicine.Eli Lilly's substantial investment in orforglipron stock ahead of its anticipated approval further indicates confidence in their product pipeline amidst growing competition from Novo Nordisk's Wegovy pill abroad. This competitive landscape highlights increasing interest and investment in innovative treatments for metabolic diseases.Overall, these developments illustrate a dynamic interplay between scientific innovation, regulatory scrutiny, and strategic corporate maneuvers that shape healthcare's future. As companies push technological boundaries, regulators face ongoing challenges in adapting frameworks that ensure patient safety while fostering innovation. The outcomes of these processes will significantly influence not only patient access to cutting-edge therapies but also set precedents for future drug development and approval pathways. As these trends unfold, stakeholders across the industry must remain agile, informed, and collaborative to navigate this evolving landscape effectively.Looking back at 2025, it was a tSupport the show

In this episode of the Gladden Longevity Podcast, Dr. Jeffrey Gladden speaks with Dr. Anthony Beck about the evolving landscape of functional medicine and the importance of personalized health approaches. They discuss the challenges patients face in navigating conflicting health information, the significance of integrating multiple health assessments, and the role of genetics in understanding individual health. Dr. Beck emphasizes the need for collaboration among healthcare providers and the empowerment of patients in their health journeys, advocating for a comprehensive and individualized approach to wellness.    For Audience ·       Use code 'Podcast10' to get 10% OFF on any of our supplements at https://gladdenlongevityshop.com/ !    Takeaways ·       Dr. Beck emphasizes the importance of a comprehensive approach to health. ·       Personal experiences often shape a practitioner's journey in medicine. ·       Functional medicine is evolving and adapting to new challenges. ·       Patients often face conflicting information in the health space. ·       Understanding personal health data is crucial for effective treatment. ·       Integrating multiple health assessments provides a clearer picture. ·       Genetics play a role, but they don't dictate health outcomes. ·       Social media can complicate health information and trends. ·       Collaboration among healthcare providers enhances patient care. ·       Empowering patients to take charge of their health is essential.   Chapters 00:00 Introduction to Longevity and Education 03:38 Personal Journey and Background of Dr. Beck 07:49 Transitioning to Functional Medicine 10:54 Navigating the Information Overload 14:35 The Importance of Individualized Medicine 18:22 Creating a Comprehensive Testing Framework 21:10 Understanding Genetic Testing and Personalized Medicine 24:14 The Importance of Foundational Health Data 27:10 Navigating the Longevity Space: Myths and Realities 31:19 The Complexity of Health: Beyond Simple Solutions 33:54 The Role of Collaboration in Patient Care 37:51 Empowering Patients: Taking Control of Health Decisions   To learn more about Dr. Anthony Beck: Email:  dragb@dranthonygbeck.com Website: balanceprotocol.com Instagram: @balanceprotocol Facebook: @balanceprotocol   Reach out to us at:    Website: https://gladdenlongevity.com/     Facebook: https://www.facebook.com/Gladdenlongevity/    Instagram: https://www.instagram.com/gladdenlongevity/?hl=en     LinkedIn: https://www.linkedin.com/company/gladdenlongevity    YouTube: https://www.youtube.com/channel/UC5_q8nexY4K5ilgFnKm7naw       Gladden Longevity Podcast Disclosures Production & Independence The Gladden Longevity Podcast and Age Hackers are produced by Gladden Longevity Podcast, which operates independently from Dr. Jeffrey Gladden's clinical practice and research at Gladden Longevity in Irving, Texas. Dr. Gladden may serve as a founder, advisor, or investor in select health, wellness, or longevity-related ventures. These may occasionally be referenced in podcast discussions when relevant to educational topics. Any such mentions are for informational purposes only and do not constitute endorsements. Medical Disclaimer The Gladden Longevity Podcast is intended for educational and informational purposes only. It does not constitute the practice of medicine, nursing, or other professional healthcare services — including the giving of medical advice — and no doctor–patient relationship is formed through this podcast or its associated content. The information shared on this podcast, including opinions, research discussions, and referenced materials, is not intended to replace or serve as a substitute for professional medical advice, diagnosis, or treatment. Listeners should not disregard or delay seeking medical advice for any condition they may have. Always seek the guidance of a qualified healthcare professional regarding any questions or concerns about your health, medical conditions, or treatment options. Use of information from this podcast and any linked materials is at the listener's own risk. Podcast Guest Disclosures Guests on the Gladden Longevity Podcast may hold financial interests, advisory roles, or ownership stakes in companies, products, or services discussed during their appearance. The views expressed by guests are their own and do not necessarily reflect the opinions or positions of Gladden Longevity, Dr. Jeffrey Gladden, or the production team. Sponsorships & Affiliate Disclosures To support the creation of high-quality educational content, the Gladden Longevity Podcast may include paid sponsorships or affiliate partnerships. Any such partnerships will be clearly identified during episodes or noted in the accompanying show notes. We may receive compensation through affiliate links or sponsorship agreements when products or services are mentioned on the show. However, these partnerships do not influence the opinions, recommendations, or clinical integrity of the information presented. Additional Note on Content Integrity All content is carefully curated to align with our mission of promoting science-based, ethical, and responsible approaches to health, wellness, and longevity. We strive to maintain the highest standards of transparency and educational value in all our communications.

Send us a textIs there a better way to heal—one that doesn't rely on endless prescriptions?In this episode of Unlimited with Elisabeth Carson, Elisabeth Carson sits down with Sam Tejada, a former firefighter turned leader in biohacking, longevity, and personalized medicine.Sam shares how years on the front lines of emergency medicine exposed the flaws in the traditional healthcare system—and what he discovered when he shifted into preventative and functional medicine. This conversation explores how data-driven diagnostics, lifestyle changes, and individualized health strategies can completely change the way we heal.If you're interested in biohacking, longevity, functional medicine, or taking a proactive approach to your health, this episode breaks it down in a clear, grounded way—without hype or extremes.✨ Follow Me or Join the Journey:Your first step towards peace: https://unlimitedmeditationpack.com/Text UNLIMITED to (954) 539-1259 for updates on when Elisabeth goes live, drops a new podcast, or exclusive updates on what's happening with her community

In this episode of The Better Life, Dr. Pinkston welcomes back her favorite compounding pharmacist, Ray Solano of PD Labs. Together, they pull back the curtain on the skincare industry, revealing why a high price tag doesn't always equal high quality. Ray introduces his new Skin Lasting line—pharmacist-designed formulations that prioritize stable, bioavailable ingredients like Vitamin C, glutathione palmitate, and GHK copper peptides over fancy packaging. The conversation also tackles the "Super Bowl of Sugar" and its impact on internal health, which invariably reflects on the skin. Beyond aesthetics, Dr. Pinkston and Ray discuss the critical role of compounding pharmacies in making healthcare affordable and customized. From natural thyroid solutions to tailored GLP-1 weight loss dosages, learn how personalized medicine can save you money and reduce side effects by giving you exactly what your body needs. Key Takeaways from the Show Inside-Out Health: Your skin is a window into your gut health; issues like eczema or psoriasis are often internal signals. The "Skin Lasting" Line: Ray explains the science behind his new serums, including the C+ Serum for daily defense and Lift Up for collagen production. The Compounding Advantage: Why "one size fits all" dosages in pharmaceutical medicine often fail patients and how customization can improve outcomes. Affordability: Discover how compounding pharmacies can offer significant savings on medications like natural thyroid and peptides. Special Offer: Listeners can get $25 off their prescription at PD Labs by mentioning Better Life TV or Dr. Pinkston. See omnystudio.com/listener for privacy information.

Whether you're curious about the emotional side of healthcare, searching for ways to take more ownership of your wellbeing, or interested in holistic approaches to longevity and healing, this episode is packed with wisdom, actionable insights, and heartfelt stories.Eric Pennington is joined by Dr. Mark Sherwood for an eye-opening conversation about the crossroads of healthcare, emotional intelligence, and the choices we make around our well-being.In this episode, Eric and Dr. Sherwood dig deep into the emotional impact of health challenges, the staggering rise in lifestyle-related diseases, and how our everyday decisions—from what we eat to how we respond to stress—shape both our physical and emotional health. Dr. Sherwood shares fascinating perspectives on the Standard American Diet, the addictive nature of certain foods, and the importance of trust and empathy between doctor and patient.You'll also learn how Dr. Sherwood and his wife, Dr. Michelle Sherwood, have built an alternative medical practice centered on treating the whole person—spiritually, emotionally, mentally, and physically. Mark offers practical advice for managing healthcare costs, becoming more intentional about your health, and fostering hope and compassion in medical interactions.Moments00:00 America's Health Crisis Worsens05:11 "Processed Foods as Addictive Drugs"07:34 "Relearning Lifestyle Beyond GLP1"09:50 Focusing on Positivity First14:44 Specialist's Approach to Personalized Care18:46 "Creating Alternative Healthcare Systems"20:51 "Rethinking Health Savings Systems"25:17 Webinar for Transparency and Engagement28:40 Holistic Health and Spiritual Connection32:05 Freedom to Choose Beliefs33:50 "Power of the Professional Pause"37:26 "Patient Recognition and Connection"40:46 "Lost Personal Connection Today"44:08 Personalized Medicine for Diabetes48:14 Women's Health Dismissal Struggles52:29 "Longevity and Health Optimization"56:10 "Mark's Inspiring Message Shared"Here are 3 thought-provoking takeaways:Healthcare Is More Than Just Medication and Diagnosis - Dr. Sherwood advocates for a partnership with patients, focusing on trust, empathy, and really listening to their stories. Creating genuine relationships leads to better health outcomes—and patients know when you truly care.Lifestyle Choices Account for the Majority of Our Health - The conversation highlights that up to 90% of recurring health conditions are tied to lifestyle, not just genetics or bad luck. Nutrition, sleep, movement, and stress management are critical pillars—and we have more control than we think.Treat the Whole Person, Not Just the Symptoms - Mark and Michelle Sherwood's practice looks at physical, emotional, spiritual, and intellectual health—helping people feel seen, heard, and valued. It's a reminder that no one is defined by a diagnosis; we are all more than our medical charts.Mark Sherwood, Naturopathic Doctor (ND) and Michele L. Neil-Sherwood, Doctor of Osteopathy (DO), have a full-time wellness-based medical practice in Tulsa, OK called the Functional Medical Institute where they adopt a whole person approach, which is outcome based looking at each individual's unique needs. Their goal is to lead people down a pathway of true healing. To that end, there are two purposes: 1. To eradicate all self-imposed, choice driven disease conditions, and 2. To eliminate the usage of unnecessary medications. Through their unique clinic, various diagnostic tests are used, healing and prevention of common disease patterns are the norm. The couple has co-authored four Amazon #1...

Dr. Eric Gordon—Medical Director at Gordon Medical Associates and President of the Gordon Medical Research Center—joins Dr. Karlfeldt for a wide-ranging conversation on what it really takes to help “end-of-the-line” patients with complex, chronic illness. With 45+ years of clinical experience and deep involvement in research on ME/CFS, Lyme disease, and autoimmune conditions, Dr. Gordon offers a grounded, clinician-to-clinician look at why so many patients remain undiagnosed, misunderstood, or stuck despite seeing multiple providers.In this episode, you'll learn why chronic illness is rarely “in the book,” and why recovery often requires detective work across toxin load, infectious burden, genetics, immune dysfunction, and environmental triggers. Dr. Gordon breaks down how modern medicine's siloed specialties can miss multi-system patterns—and why tools like advanced testing and AI may become essential to sift exploding research (like microbiome discoveries) into something clinically useful. They also explore the evolving landscape of long COVID research, the importance of identifying patient subtypes (instead of lumping everyone into one diagnosis), and what this shift could mean for faster, more affordable healing.If you've tried the “usual” protocols and still don't improve, this conversation reframes the journey: why complexity doesn't mean hopelessness—and how the next wave of systems biology, smarter data-mining, and targeted interventions may finally change the game for chronic fatigue, Lyme, mold illness, and beyond.Key Topics CoveredWhy “complex chronic illness” usually isn't a simple diagnosis—and why that matters for treatmentThe “end-of-the-line” patient: what it means when you've already seen many good doctorsHow toxin load, infections, genetics, and terrain combine into a personalized illness patternWhy medical silos and protocol-based care often fail complex patientsMold exposure and mycotoxin sensitivity: why environment can block progressMast cell activation and reactivity: why treatment tolerance can be a major barrierThe microbiome information explosion—and why AI is becoming necessary to interpret itGarbage-in/garbage-out in AI: why context and quality data still matterLong COVID as a turning point: validating post-viral illness and advancing immune researchThe importance of subtyping ME/CFS, long COVID, and Lyme presentations to find what actually works _______________________________The Karlfeldt Center offers the most cutting-edge and comprehensive Lyme therapies. To schedule a Free 15-Minute Discovery Call with a Lyme Literate Naturopathic Doctor at The Karlfeldt Center, call 208-338-8902 or email info@TheKarlfeldtCenter.comCheck out Dr. K's Ebook: Breaking Free From Lyme: A Comprehensive Guide to Healing and Recovery here: https://store.thekarlfeldtcenter.com/products/breaking-free-from-lymeUse the code LYMEPODCAST for a 100% off discount!

In this episode of the BiohackingVille podcast, host Rob Rene sits down with Scott Nelson at the TAM Center in Tijuana, Mexico. They discuss alternative treatments for cancer and autoimmune diseases that exist outside the traditional medical system. Scott explains how the center was established to offer cutting-edge, customized treatments that aren't available in the United States due to regulatory and financial restrictions. They delve into the importance of personalized medicine, the role of nutrition and exercise in treatment, and the benefits of integrated medical and scientific collaboration at the center. The episode also highlights the challenges of the US medical system and the innovative strides being made in Mexico..00:00 Introduction to BiohackingVille00:47 Welcome to the TAM Center01:23 Scott Nelson's Journey to Tijuana01:48 Reopening the Hospital and Early Successes02:19 Innovative Cancer Treatments and Misdiagnosis04:31 Challenges and Advantages of Operating in Mexico08:00 Personalized Medicine and the Role of CPI08:42 The Importance of Comprehensive Testing14:14 Integrating Science and Medicine on the Sixth Floor15:41 Conclusion and Final Thoughts

As 2026 gets underway we know that many take time around this new beginning to improve not only their physical, but also their mental health. With that in mind, we're rerunning an episode with Leanne Williams on the future of depression care. Leanne is an expert on clinical depression and is working on new ways to more precisely diagnose depression in order to develop more effective treatment. For anyone who has suffered from depression or knows someone who has, it's an episode that provides hope for what's on the horizon. We hope you'll take another listen and also share this episode with anyone who you think may benefit from the conversation. Episode Reference Links:Stanford Profile: Leanne WilliamsConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Leanne Williams, a professor of Psychiatry and Behavioral Science at Stanford University.(00:01:43) What Is Depression?Distinguishing clinical depression from everyday sadness.(00:03:31) Current Depression Treatment ChallengesThe trial-and-error of traditional depression treatments and their timelines.(00:06:16) Brain Mapping and Circuit DysfunctionsAdvanced imaging techniques and their role in understanding depression.(00:09:03) Diagnosing with Brain ImagingHow brain imaging can complement traditional diagnostic methods in psychiatry.(00:10:22) Depression BiotypesIdentifying six distinct biotypes of depression through brain imaging.(00:12:31) Cognitive Features of DepressionHow cognitive impairment plays a major role in certain depression biotypes.(00:14:11) Matching Treatments to BiotypesFinding appropriate treatments sooner using brain-based diagnostics.(00:15:38) Expanding Treatment OptionsPersonalizing therapies and improving treatment outcomes based on biotypes.(00:19:03) AI in Depression TreatmentUsing AI to refine biotypes and predict treatment outcomes with greater accuracy.(00:22:15) Psychedelics in Depression TreatmentThe potential for psychedelic drugs to target specific biotypes of depression.(00:23:46) Expanding the Biotypes FrameworkIntegrating multimodal approaches into the biotype framework.(00:27:29) Reducing Stigma in DepressionHow showing patients their brain imaging results reduces self-blame and stigma.(00:29:38) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Send us a textHow individuals vary in responses to carbs, fibers, and fats.TOPICS DISCUSSED:Personalized health profiling: Snyder's lab sequences genomes and measures molecules from blood, urine, and microbiomes to detect diseases early, emphasizing data-driven discovery over assumptions.Fiber variations and effects: Responses to dietary fibers vary individually, with microbiome playing a key role.Glycemic responses to carbs: People spike differently to foods like rice, potatoes, or bread; tied to insulin resistance subtypes in muscles, liver, or pancreas.Type 2 diabetes heterogeneity: 90% of diabetes cases are type 2 with subtypes like muscle or hepatic resistance; triggers include genetics and infections, with prediabetes often undetected.Continuous glucose monitors (CGMs): Affordable tools measure glucose every five minutes, revealing personal food triggers; spikes link to risks like cardiovascular disease and cancer.Lipidomics: Lipids are diverse, serving as energy sources, structural components, and signaling molecules; understudied but key in metabolism and gene expression.Maternal health & pregnancy: Metabolomics shows thousands of changes, including hormone shifts; cord blood analysis reveals fetal nutrient use and drug transfers, with markers for preterm birth or healthy outcomes.Future research: Exploring epigenetic changes in diabetes, personalized nutrition mitigation, and digital markers from wearables for mental health tied to diet and gut-brain axis.ABOUT THE GUEST: Michael Snyder, PhD is the Stanford W. Ascherman Professor of Genetics and former chair of the Department of Genetics at Stanford University School of Medicine, where he directs the Center for Genomics and Personalized Medicine.Support the showHealth Products by M&M Partners: SporesMD: Premium mushrooms products (gourmet mushrooms, nootropics, research). Use code TRIKOMES for 20% off. Lumen device: Optimize your metabolism for weight loss or athletic performance. MINDMATTER gets you 15% off. AquaTru: Water filtration devices that remove microplastics, metals, bacteria, and more from your drinking water. Through link, $100 off AquaTru Carafe, Classic & Under Sink Units; $300 off Freestanding models. Seed Oil Scout: Find restaurants with seed oil-free options, scan food products to see what they're hiding, with this easy-to-use mobile app. KetoCitra—Ketone body BHB + electrolytes formulated for kidney health. Use code MIND20 for 20% off any subscription (cancel anytime) For all the ways you can support my efforts

In this episode of Health Matters, host Courtney Allison is joined by Dr. Rekha Kumar, endocrinologist and primary care physician at NewYork-Presbyterian and Weill Cornell Medicine, to unpack the science behind aging well. They discuss biohacking, longevity, and health span, separating evidence-based strategies from social media hype and exploring what truly helps us age well.What You'll Learn in This EpisodeWhat “biohacking” really means● How biohacking ranges from simple lifestyle optimization to high-tech, experimental interventions● The difference between lifespan (how long you live) and health span (how long you live well)The Longevity Pyramid● Why the foundation of healthy aging is built on:SleepMovement and strength trainingNutritionStress managementSocial connection● How advanced tools and supplements sit at the top—and why they should never replace the basicsWearables and Tracking● How devices like smartwatches, glucose monitors, and fitness trackers can support behavior change● When tracking becomes counterproductive or stressfulPeptides and “Anti-Aging” Supplements● What's proven (e.g., metformin, GLP-1 receptor agonists)● What's still experimental or under-studied (BPC-157, sermorelin, NAD boosters)Nootropics and Cognitive Enhancers● Everyday nootropics like caffeine● The role of L-theanine for “calm focus”● Myths around perfectly timed caffeine and cortisol rhythmsNutrigenomics and Personalized Nutrition● How genes can influence responses to foods (e.g., lactose intolerance, APOE and saturated fat)● Why many direct-to-consumer genetic tests may overpromiseThe Gut Microbiome● The role of Akkermansia muciniphila in metabolic health● How medications like metformin and GLP-1s may positively shift gut bacteria● What's still unknown about probiotic supplementationGenetic and Biomarker Testing● The difference between actionable medical insights and “information overload”● Why results of unknown significance can cause unnecessary anxietyThe Big Takeaways● There are no true shortcuts to longevity● Sustainable habits beat quick fixes● Our biology is built for rhythms, not constant optimizationFeatured ExpertAbout Rekha B. Kumar, M.D., M.S.Dr. Rekha B. Kumar is an attending endocrinologist at NewYork-Presbyterian/Weill Cornell Medical Center and an associate professor of Clinical Medicine at Weill Cornell Medicine. She specializes in adult primary care and endocrinology and has academic expertise in the diagnosis and treatment of various endocrine disorders, including obesity/weight management, type 2 diabetes, polycystic ovarian syndrome (PCOS), thyroid disorders, as well as metabolic bone disease.Dr. Kumar completed her undergraduate studies at Duke University and received her masters degree in Physiology from Georgetown University. She received her M.D. from New York Medical College and completed her residency training in Internal Medicine at NewYork-Presbyterian/Weill Cornell Medical Center. Dr. Kumar obtained her clinical fellowship in the combined Diabetes, Endocrinology, and Metabolism program at the NewYork-Presbyterian/Weill Cornell Medical Center and the Memorial Sloan Kettering Cancer Center. Dr. Kumar is Board Certified in Internal Medicine, Endocrinology, Diabetes, & Metabolism, and Obesity Medicine.Coming Up NextIn the next episode of Health Matters, we'll explore brain health and the short- and long-term effects of alcohol on the brain with Dr. Hugh Cahill. Subscribe and follow Health Matters on Apple Podcasts, Spotify, or wherever you listen to stay up to date with expert-driven conversations on living well at every stage of life.About Health MattersHealth Matters is your bi-weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine.To learn more visit: https://healthmatters.nyp.org

Understanding and Treating Complex Illnesses with Dr. Neil Nathan, author of “Toxic 2nd Edition: Heal Your Body from Mold Toxicity, Lyme Disease, Multiple Chemical Sensitivities, and Chronic Environmental Illness.” Dr. Nathan shares his expertise on the multifaceted nature of chronic illnesses, which often defy simple categorization and may be misdiagnosed as psychiatric issues. The discussion covers the impact of environmental toxins, electromagnetic fields, and infections like Lyme disease and long COVID. Dr. Nathan also highlights the importance of understanding inflammation's complex pathways and offers suggestions for both elimination of root causes and restoration of immune system functionality. The episode provides insights into new diagnostic tools and treatment methodologies for persistent and intrusive health issues.

In this episode of the Gladden Longevity Podcast, Dr. Jeffrey Gladden and Kashif Khan discuss the intersection of genetics, health, and longevity. Kashif shares his personal journey from illness to founding the DNA company, emphasizing the importance of personalized medicine and genetic testing. They explore the unique health challenges faced by women, the impact of trauma and stress on health, and the need for individualized approaches in biohacking. The conversation highlights the significance of understanding hormone metabolism and the role of genetics in parenting, ultimately advocating for a comprehensive analysis of health to achieve optimal outcomes.   For Audience ·       Use code 'Podcast10' to get 10% OFF on any of our supplements at https://gladdenlongevityshop.com/ !    Takeaways ·        Genetics play a crucial role in understanding individual health. ·        Personalized medicine is essential for effective treatment. ·        Women face unique health challenges that are often overlooked. ·        Understanding hormone metabolism is key to preventing health issues. ·        Trauma and stress can significantly impact health outcomes. ·        Biohacking should be individualized, not one-size-fits-all. ·        Nervous system regulation is vital for overall health. ·        Genetic predispositions can reveal superpowers and vulnerabilities. ·        Parenting can be enhanced through understanding children's genetics. ·        Comprehensive analysis is necessary for accurate health assessments.     Chapters 00:00 Introduction to Kashif and His Journey 05:37 The Role of Genetics in Health 08:12 Understanding Individual Health Through Multiple Lenses 11:12 The Importance of Personalized Medicine 14:00 The Intersection of Genetics and Trauma 17:04 Navigating the Biohacking Landscape 19:54 The Impact of Stress and Anxiety on Health 22:59 Transforming Trauma into Superpowers 29:04 The Impact of Social Media on Identity 30:01 Understanding Genetic Potential in Children 32:32 Personalized Parenting Through Genetic Insights 38:39 Women's Health: A Neglected Area 41:25 Hormonal Health and Cancer Risks 47:32 The Precision of Hormonal Treatments   To learn more about Kashif: Email:  kash@kashkhanofficial.com Website: https://kashkhanofficial.com/   Reach out to us at:    Website: https://gladdenlongevity.com/     Facebook: https://www.facebook.com/Gladdenlongevity/    Instagram: https://www.instagram.com/gladdenlongevity/?hl=en     LinkedIn: https://www.linkedin.com/company/gladdenlongevity    YouTube: https://www.youtube.com/channel/UC5_q8nexY4K5ilgFnKm7naw       Gladden Longevity Podcast Disclosures Production & Independence The Gladden Longevity Podcast and Age Hackers are produced by Gladden Longevity Podcast, which operates independently from Dr. Jeffrey Gladden's clinical practice and research at Gladden Longevity in Irving, Texas. Dr. Gladden may serve as a founder, advisor, or investor in select health, wellness, or longevity-related ventures. These may occasionally be referenced in podcast discussions when relevant to educational topics. Any such mentions are for informational purposes only and do not constitute endorsements. Medical Disclaimer The Gladden Longevity Podcast is intended for educational and informational purposes only. It does not constitute the practice of medicine, nursing, or other professional healthcare services — including the giving of medical advice — and no doctor–patient relationship is formed through this podcast or its associated content. The information shared on this podcast, including opinions, research discussions, and referenced materials, is not intended to replace or serve as a substitute for professional medical advice, diagnosis, or treatment. Listeners should not disregard or delay seeking medical advice for any condition they may have. Always seek the guidance of a qualified healthcare professional regarding any questions or concerns about your health, medical conditions, or treatment options. Use of information from this podcast and any linked materials is at the listener's own risk. Podcast Guest Disclosures Guests on the Gladden Longevity Podcast may hold financial interests, advisory roles, or ownership stakes in companies, products, or services discussed during their appearance. The views expressed by guests are their own and do not necessarily reflect the opinions or positions of Gladden Longevity, Dr. Jeffrey Gladden, or the production team. Sponsorships & Affiliate Disclosures To support the creation of high-quality educational content, the Gladden Longevity Podcast may include paid sponsorships or affiliate partnerships. Any such partnerships will be clearly identified during episodes or noted in the accompanying show notes. We may receive compensation through affiliate links or sponsorship agreements when products or services are mentioned on the show. However, these partnerships do not influence the opinions, recommendations, or clinical integrity of the information presented. Additional Note on Content Integrity All content is carefully curated to align with our mission of promoting science-based, ethical, and responsible approaches to health, wellness, and longevity. We strive to maintain the highest standards of transparency and educational value in all our communications.

On the Flyover Conservatives Show, we sat down with Dr. Nick and Leah Wilson for a shocking deep dive into the rapid push for newborn DNA harvesting and the hidden dangers behind the rise of “personalized medicine.” They uncover how whole-genome sequencing, gene-therapy failures, national DNA databases, and the medical-industrial complex are converging into a system of unprecedented control over the next generation. This conversation will wake up parents, challenge long-held assumptions, and equip families to step back into the driver's seat of their health decisions.On the Flyover Conservatives Show, we sat down with Dr. Nick and Leah Wilson for a shocking deep dive into the rapid push for newborn DNA harvesting and the hidden dangers behind the rise of “personalized medicine.” They uncover how whole-genome sequencing, gene-therapy failures, national DNA databases, and the medical-industrial complex are converging into a system of unprecedented control over the next generation. This conversation will wake up parents, challenge long-held assumptions, and equip families to step back into the driver's seat of their health decisions.TO WATCH ALL FLYOVER CONTENT: www.theflyoverapp.comTO WATCH ALL FLYOVER CONTENT: www.theflyoverapp.comFollow and Subscribe on YouTube: https://www.youtube.com/@TheFlyoverConservativesShow Follow and Subscribe on YouTube: https://www.youtube.com/@TheFlyoverConservativesShow Dr. Nick and Leah WilsonDr. Nick and Leah WilsonWEBSITE: www.StandForHealthFreedom.com WEBSITE: www.StandForHealthFreedom.comwww.StandForHealthFreedom.com BOOK: https://a.co/d/d9dbqTh BOOK: https://a.co/d/d9dbqThhttps://a.co/d/d9dbqTh Dr. Nick Wilson is a chiropractor, wellness expert, and leading voice in the movement to exit conventional medicine and return to principles of natural health, vitality, and personal responsSend us a message... we can't reply, but we read them all!Support the show► ReAwaken America- text the word FLYOVER to 918-851-0102 (Message and data rates may apply. Terms/privacy: 40509-info.com) ► Kirk Elliott PHD - http://FlyoverGold.com ► My Pillow - https://MyPillow.com/Flyover ► ALL LINKS: https://sociatap.com/FlyoverConservatives

AI accelerates drug discovery while steroids turn teens into aggressive strangers. Dr. Michael Israetel explores our pharmaceutical crossroads here!Full show notes and resources can be found here: jordanharbinger.com/1209What We Discuss with Michael Israetel:GLP-1 drugs like Tirzepatide offer massive health benefits beyond weight loss — reducing inflammation, improving brain health, and decreasing addiction behaviors, even for people already in good shape.Steroids don't just amplify personality — they specifically amplify masculine traits like aggression and reduce empathy. Starting young can permanently rewire your brain's emotional and social processing.AI is about to revolutionize medicine by testing millions of drug candidates virtually, creating treatments 10x more effective with 10x fewer side effects. We're entering the pharmaceutical iPhone moment.The "only take drugs when sick" mindset worked in the 20th century, but is becoming dangerously outdated — like refusing elevators because you prefer human operators.When your diet plateaus, take a week-long break eating at maintenance. Your stress hormones will drop, body water will flush out, and you'll often look leaner than before.And much more...And if you're still game to support us, please leave a review here — even one sentence helps! Sign up for Six-Minute Networking — our free networking and relationship development mini course — at jordanharbinger.com/course!Subscribe to our once-a-week Wee Bit Wiser newsletter today and start filling your Wednesdays with wisdom!Do you even Reddit, bro? Join us at r/JordanHarbinger!This Episode Is Brought To You By Our Fine Sponsors:Saily: 15% off: saily.com/jordanharbinger, code JORDANHARBINGERDripDrop: 20% off: DripDrop.com, code JORDANLinkedIn Jobs: Post your job for free: linkedin.com/jordanQuince: Free shipping & 365-day returns: quince.com/jordanBetterHelp: 10% off first month: betterhelp.com/jordanSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.